Founded in 1946, it remained intentionally small, operating as a self-governing community with students following self-designed degree plans culminating in a thesis. In 1998 the college added a graduate school.The college closed at the end of the 2019–2020 academic year and gifted its endowment to Emerson College in Boston to create the Marlboro Institute of Liberal Arts and Interdisciplinary Studies at Emerson College.
Introduction and Objective: Suboptimal glycemic control in persons with type 1 diabetes (PwT1D) increases the risk of costly complications. Control-IQ technology (CIQ) improves metabolic control and has been shown to reduce HCRU. The objective of this study is to estimate 1-year impact of adopting CIQ for PwT1D. Methods: This model compared 5,500 PwT1D on multiple daily injections (MDI) versus incremental adoption of CIQ by 20%, 25%, and 30% over 1 year for a health plan with 1M lives across Commercial, Medicare, and Medicaid lines of business (LOB). T1D-related serious events requiring hospitalizations (i.e., MI, stroke, ulcer, CHF, and neuropathy) were modeled using published incidence rates and payer-specific length of stay (LOS) data. Results: For 25% CIQ adoption (1,375 PwT1D), event rates decreased by 5% for MI (0.61 to 0.58), 5% for stroke (0.11 to 0.11), 4% for ulcer (0.14 to 0.14), 6% for CHF (0.13 to 0.12), and 11% for neuropathy (14.23 to 12.66). This corresponded to a LOS reduction of 5%, 3%, 4%, 6% and 11%, respectively (Table 1). Results consistently showed greater HCRU reductions with higher CIQ uptake across all LOB and adoption rates. Conclusion: Adoption of CIQ is projected to provide meaningful reductions in diabetes-related hospitalization events in a U.S. health plan. Higher adoption rates result in greater reductions in clinical events and LOS. Disclosure S. Cheng: Consultant; Tandem Diabetes Care, Inc. S.M. Wang: Employee; Tandem Diabetes Care, Inc. Stock/Shareholder; Tandem Diabetes Care, Inc. A.J. Ambegaonkar: Consultant; Tandem Diabetes Care, Inc, Pfizer Inc, AstraZeneca, Janssen Pharmaceuticals, Inc, Abbott Diagnostics, Alexion Pharmaceuticals, Inc, Otsuka America Pharmaceutical, Inc, Sanofi, Merck & Co., Inc. B.V. Patel: Employee; Tandem Diabetes Care, Inc. Stock/Shareholder; Tandem Diabetes Care, Inc.
A subset of an abelian group is sequenceable if there is an ordering $(x_1, \ldots, x_k)$ of its elements such that the partial sums $(y_0, y_1, \ldots, y_k)$, given by $y_0 = 0$ and $y_i = \sum_{j=1}^i x_j$ for $1 \leq i \leq k$, are distinct, with the possible exception that we may have $y_k = y_0 = 0$. We demonstrate the sequenceability of subsets of size $k$ of $\mathbb{Z}_n \setminus \{ 0 \}$ when $n = mt$ in many cases, including when $m$ is either prime or has all prime factors larger than $k! /2$ for $k \leq 11$ and $t \leq 5$ and for $k=12$ and $t \leq 4$. We obtain similar, but partial, results for $13 \leq k \leq 15$. This represents progress on a variety of questions and conjectures in the literature concerning the sequenceability of subsets of abelian groups, which we combine and summarize into the conjecture that if a subset of an abelian group does not contain $0$ then it is sequenceable.
American EthnologistVolume 49, Issue 2 p. 279-280 Book Reviews Aerial Imagination in Cuba: Stories from Above the Rooftops. Alexandrine Boudreault-Fournier. Illustrated by José Manuel Fernández Lavado. London: Routledge, 2020. 126 pp. CAROL HENDRICKSON, CAROL HENDRICKSON Marlboro CollegeSearch for more papers by this author CAROL HENDRICKSON, CAROL HENDRICKSON Marlboro CollegeSearch for more papers by this author First published: 14 April 2022 https://doi.org/10.1111/amet.13077Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume49, Issue2May 2022Pages 279-280 RelatedInformation
